Navigation Links
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Date:2/11/2008

rin and danaparoid. These agents all require therapy by injection and are all potent anticoagulants, which are blood thinners capable of inducing bleeding. Sulodexide, on the other hand, is given orally and, in this form, has demonstrated little, if any, anticoagulant effects to date.

Keryx owns the exclusive rights to sulodexide for the treatment of diabetic nephropathy in North America, Japan and certain other markets outside of Europe. Diabetic nephropathy is a long-term complication of diabetes in which the kidneys are progressively damaged. Sulodexide is a glycosaminoglycan compound with structural similarities to the broad family of marketed heparins and low molecular weight heparins. This drug has been marketed in a number of European, Asian and South American countries for many years by our licensor for certain cardiovascular conditions and has an established safety profile at the doses used for such indications. Additionally, it has been demonstrated in multiple clinical trials conducted in Europe and the U.S., including two randomized, double-blind, placebo-controlled Phase II studies, that sulodexide can reduce urinary protein excretion in patients with diabetic nephropathy.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. In addition to sulodexide, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical- stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in- class, oral modulator of Akt, a pathway associated with tumo
'/>"/>

SOURCE Keryx Biopharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
4. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock consisting of 1,475,506 shares to be ... by certain of its stockholders. In addition, Nevro expects ... up to an additional 590,202 shares of common stock ...
(Date:6/1/2015)... , June 1, 2015 NEOVIA ONCOLOGY ... engaged in the development and commercialization of novel, ... it has met with the U.S. Food and ... filing of an Investigational New Drug (IND) application ... a result of the meeting, Neovia has clarified ...
(Date:6/1/2015)... Novel t reatments   entering the squamous ... GBI Research . The ... primarily by the introduction of numerous premium therapies, particularly in ... combine with generic chemotherapies. Analysis from business intelligence ... to 2020 - forecasts the value of the NSCLC ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Neovia Oncology Announces First IND Meeting 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3
... Pharmasset, Inc.,(Nasdaq: VRUS ), a clinical stage pharmaceutical ... viral,infections, reported financial results for the fiscal year ended September ... cash and cash,equivalents and short term investments. , ... Clevudine , ...
... PHILADELPHIA, December 11, Rosetta Genomics, Ltd. (NASDQ: ROSG), ... the,commercial availability of its first diagnostic test, miRview(TM) ... Genomics,CLIA-certified lab in Philadelphia. , ... may contact 1-888-522-7971, or visit the,company,s website ...
Cached Medicine Technology:Pharmasset Reports Fiscal Year End 2008 Financial Results 2Pharmasset Reports Fiscal Year End 2008 Financial Results 3Pharmasset Reports Fiscal Year End 2008 Financial Results 4Pharmasset Reports Fiscal Year End 2008 Financial Results 5Pharmasset Reports Fiscal Year End 2008 Financial Results 6Pharmasset Reports Fiscal Year End 2008 Financial Results 7Pharmasset Reports Fiscal Year End 2008 Financial Results 8Pharmasset Reports Fiscal Year End 2008 Financial Results 9Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 5
(Date:6/1/2015)... June 01, 2015 KC and Monica ... $88,000 of the best superfood products in ... floods in Texas. , "Monica and I are ... News in distributing Living Fuel Super Meals - SuperBerry®, ... millennial floods in Texas," KC Craichy said. "We have ...
(Date:6/1/2015)... Atlanta, GA (PRWEB) June 01, 2015 ... leading publisher of clinical journals in the areas of ... pleased to announce that it has expanded upon its ... newest journal, Hospital Medicine Practice, in a mobile ... smartphones and tablets. , “We are very excited ...
(Date:6/1/2015)... The session, entitled “Building the Blueprint for Tomorrow’s Vehicle ... Automotive Americas, senior representatives from Ford and Delphi, ... by Andy Gryc of CX3 Marketing. The discussion will ... software in connected vehicles and autonomous cars, and will ... ecosystem can fit into new vehicle software. , ...
(Date:6/1/2015)... Strategic Radiology (SR) announced today that Rome Radiology Group ... SR coalition of progressive, independent radiology groups geographically dispersed ... have access to collective resources in all aspects of ... of subspecialized radiology services. With the addition of RRG, ... based radiology group practices. , “We are all ...
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 It ... and sanitary in order to protect both care providers ... that there needs to be a way to put ... Line is a line of home-healthcare products that promotes ... care providers and patients safe from germs and disease. ...
Breaking Medicine News(10 mins):Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 2Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 4
... came into being in the seventies, evolved into an essential component ... increase with mounting pressure on pharma and biotech companies to lower ... projected to exceed $26.2 billion by the year 2012. , ... ...
... that allows more efficient use of larger cleanrooms. , ... ... designer, fabricator and installer of cleanrooms and cleanroom equipment ... into the AireCell line of extrusions. The new extrusion allows ...
... SuperFood with Super Antioxidant provides ... environmental stress, ORLANDO, Fla., Oct. 21 ... (Chennai, India) are jointly introducing a,new organic ... complex,of organic spirulina and astaxanthin in a ...
... 21, 2008) Gastroesophageal reflux disease (GERD) is ... in GI and primary care clinics, however physicians ... trials of medications and their own observations and ... Gastroenterological Association (AGA) Institute has published evidence-based guidelines ...
... of $25 Tickets Available for Purchase at the Pine Avenue ... Entrance to the Long Beach Convention Center, LOS ANGELES, ... The Village event tonight from 5:00 p.m. to 9:00 p.m.,at the ... Night at The Village will,transform the Long Beach Convention Center,s exhibit ...
... Promotes Positive Options, Educates about Dangers of Alcohol, ... 24 school districts have been named by the ... 2008 Alcohol Awareness Poster,Contest., The awards recognize ... message that underage drinking is dangerous. The,PLCB,s annual ...
Cached Medicine News:Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 2Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 3Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 4Health News:Gerbig Engineering Introduces 7 " Deep Extrusions for Cleanroom Construction 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 3Health News:AGA releases evidence-based GERD guidelines 2Health News:AGA releases evidence-based GERD guidelines 3Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 2Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 2Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 4
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.85 mm slit. Blade tip dimension: 14.1 mm x 2.85 mm x 3.3 mm....
Full Handle Laseredge Slit Blade Knife, 2.8 mm angled double bevel. Blade tip dimension: N/A x 2.8 mm x N/A....
Medicine Products: